AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe

News provided by

Nov 08, 2021, 08:10 ET

IRVINE, Calif., Nov. 8, 2021 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will chair a keynote panel and speak on consecutive days at the World Immunotherapy Congress Europe. The congress is part of the Festival of Biologics taking place in Basel, Switzerland, November 9-11. Dr. Keirstead's speaking details are as follows:

Keynote panel discussion: What does the future of immunotherapy hold for oncology and infections diseases?
When: Tuesday, November 9, 10:00 AM CEST
Panelists: Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, Roche Innovation Center Zurich; Jessica Flechtner, Chief Scientific Officer, Genocea Biosciences, Hans Keirstead, Chairman and CEO AIVITA Biomedical.
Location: Congress Center Basel - Basel, Switzerland

Presentation: Late-stage clinical development of a personalized vaccine platform technology for cancer and COVID-19
When: Wednesday, November 10, 11:50 AM CEST
Location: Congress Center Basel - Basel, Switzerland

About AIVITA Biomedical

Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, tumor-initiating cells, with a unique pan-antigenic approach that targets all neoantigens specific to the patient's cancer. Our patient-specific cancer treatments have shown tremendous promise in eradicating tumors, without harmful side effects, in melanoma and glioblastoma clinical studies. Our COVID-19 Vaccine Enabling Kit is targeted to emerging nations enabling point-of-care vaccine production in minimally-equipped facilities by minimally-trained third party technicians.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on a number of assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

SOURCE AIVITA Biomedical, Inc.